DK1460969T3 - Forebyggelse og behandling af ved androgen-berövelse fremkaldt osteoporose - Google Patents

Forebyggelse og behandling af ved androgen-berövelse fremkaldt osteoporose

Info

Publication number
DK1460969T3
DK1460969T3 DK02804417T DK02804417T DK1460969T3 DK 1460969 T3 DK1460969 T3 DK 1460969T3 DK 02804417 T DK02804417 T DK 02804417T DK 02804417 T DK02804417 T DK 02804417T DK 1460969 T3 DK1460969 T3 DK 1460969T3
Authority
DK
Denmark
Prior art keywords
osteoporosis
prevention
treatment
androgen deprivation
androgen
Prior art date
Application number
DK02804417T
Other languages
Danish (da)
English (en)
Inventor
Mitchell S Steiner
Sharan Raghow
Karen A Veverka
Original Assignee
Gtx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gtx Inc filed Critical Gtx Inc
Application granted granted Critical
Publication of DK1460969T3 publication Critical patent/DK1460969T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A61K31/025—Halogenated hydrocarbons carbocyclic
    • A61K31/03—Halogenated hydrocarbons carbocyclic aromatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK02804417T 2001-11-29 2002-11-27 Forebyggelse og behandling af ved androgen-berövelse fremkaldt osteoporose DK1460969T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33373401P 2001-11-29 2001-11-29
PCT/US2002/036136 WO2003047504A2 (fr) 2001-11-29 2002-11-27 Prevention et traitement de l'osteoporose induite par la privation d'androgene

Publications (1)

Publication Number Publication Date
DK1460969T3 true DK1460969T3 (da) 2008-09-01

Family

ID=23304031

Family Applications (2)

Application Number Title Priority Date Filing Date
DK02804417T DK1460969T3 (da) 2001-11-29 2002-11-27 Forebyggelse og behandling af ved androgen-berövelse fremkaldt osteoporose
DK05028100T DK1666033T3 (da) 2001-11-29 2002-11-27 Forebyggelse og behandling af ved androgenmangel fremkaldt osteoporose

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK05028100T DK1666033T3 (da) 2001-11-29 2002-11-27 Forebyggelse og behandling af ved androgenmangel fremkaldt osteoporose

Country Status (23)

Country Link
US (1) US6899888B2 (fr)
EP (5) EP2098247A3 (fr)
JP (2) JP2005515988A (fr)
KR (1) KR100658110B1 (fr)
CN (2) CN100548283C (fr)
AT (2) ATE418972T1 (fr)
AU (2) AU2002356928B2 (fr)
BR (1) BR0214801A (fr)
CA (2) CA2537913A1 (fr)
CY (2) CY1108174T1 (fr)
DE (2) DE60230687D1 (fr)
DK (2) DK1460969T3 (fr)
EA (1) EA200400744A1 (fr)
ES (2) ES2319785T3 (fr)
GE (1) GEP20094841B (fr)
HK (2) HK1068104A1 (fr)
HR (1) HRP20040547A2 (fr)
IL (2) IL162144A0 (fr)
MX (1) MXPA04005112A (fr)
PT (2) PT1460969E (fr)
SI (2) SI1460969T1 (fr)
TW (1) TWI315987B (fr)
WO (1) WO2003047504A2 (fr)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040176470A1 (en) * 1998-05-07 2004-09-09 Steiner Mitchell S. Method for treatment and chemoprevention of prostate cancer
US20040092602A1 (en) * 1998-05-07 2004-05-13 Steiner Mitchell S. Method for treatment and chemoprevention of prostate cancer
US7622503B2 (en) * 2000-08-24 2009-11-24 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
US7919647B2 (en) 2000-08-24 2011-04-05 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
US7645898B2 (en) * 2000-08-24 2010-01-12 University Of Tennessee Research Foundation Selective androgen receptor modulators and method of use thereof
US7855229B2 (en) * 2000-08-24 2010-12-21 University Of Tennessee Research Foundation Treating wasting disorders with selective androgen receptor modulators
US20070197664A1 (en) * 2001-11-29 2007-08-23 Steiner Mitchell S Prevention and treatment of androgen-deprivation induced osteoporosis
US20050080143A1 (en) * 2001-11-29 2005-04-14 Steiner Mitchell S. Treatment of androgen-deprivation induced osteoporosis
US20040214898A1 (en) * 2001-11-29 2004-10-28 Steiner Mitchell S. Methods for treating hot flashes
US20080249183A1 (en) * 2001-11-29 2008-10-09 Steiner Mitchell S Treatment of androgen-deprivation induced osteoporosis
US7524866B2 (en) * 2001-11-29 2009-04-28 Gtx, Inc. Prevention and treatment of androgen—deprivation induced osteoporosis
US20060269611A1 (en) * 2001-11-29 2006-11-30 Steiner Mitchell S Prevention and treatment of androgen-deprivation induced osteoporosis
US20070161608A1 (en) * 2001-12-06 2007-07-12 Dalton James T Selective androgen receptor modulators for treating muscle wasting
US8853266B2 (en) * 2001-12-06 2014-10-07 University Of Tennessee Research Foundation Selective androgen receptor modulators for treating diabetes
US7332525B2 (en) * 2003-01-17 2008-02-19 Castle Erik P Method of treatment of prostate cancer and composition for treatment thereof
US9884038B2 (en) 2004-06-07 2018-02-06 University Of Tennessee Research Foundation Selective androgen receptor modulator and methods of use thereof
US20110237664A1 (en) * 2004-06-07 2011-09-29 Dalton James T Selective androgen receptor modulators for treating diabetes
US9889110B2 (en) 2004-06-07 2018-02-13 University Of Tennessee Research Foundation Selective androgen receptor modulator for treating hormone-related conditions
US20060019989A1 (en) * 2004-07-21 2006-01-26 Steiner Mitchell S Compositions comprising 5-alpha reductase inhibitors and SERMs and methods of use thereof
KR20070059110A (ko) * 2004-09-03 2007-06-11 호르모스 메디칼 리미티드 안드로겐 결핍의 치료 또는 예방에 사용하는 제제의 제조를위한 선택적 에스트로겐 수용체 조절자의 용도
US20060270641A1 (en) * 2005-05-31 2006-11-30 Steiner Mitchell S Method for chemoprevention of prostate cancer
AU2006339325A1 (en) * 2005-11-09 2007-09-07 Hormos Medical Ltd. Formulations of fispemifene
EA018066B1 (ru) * 2005-11-28 2013-05-30 Джи Ти Икс, ИНК. Агент, связывающийся с ядерными рецепторами
US9409856B2 (en) 2005-11-28 2016-08-09 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
US8637706B2 (en) 2005-11-28 2014-01-28 Gtx, Inc. Nuclear receptor binding agents
US8158828B2 (en) * 2005-11-28 2012-04-17 Gtx, Inc. Nuclear receptor binding agents
US8546451B2 (en) * 2005-11-28 2013-10-01 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
US7504530B2 (en) 2007-02-14 2009-03-17 Hormos Medical Ltd. Methods for the preparation of fispemifene from ospemifene
JP5363344B2 (ja) 2007-02-14 2013-12-11 ホルモス メディカル リミテッド 治療に有用なトリフェニルブテン誘導体の調製方法
US7968603B2 (en) 2007-09-11 2011-06-28 University Of Tennessee Research Foundation Solid forms of selective androgen receptor modulators
EP2489656A1 (fr) 2007-12-21 2012-08-22 Ligand Pharmaceuticals Inc. Modulateurs de récepteurs androgènes sélectifs (sarm) et leurs utilisations
US9427418B2 (en) 2009-02-23 2016-08-30 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
US9624161B2 (en) 2009-02-23 2017-04-18 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
US10987334B2 (en) 2012-07-13 2021-04-27 University Of Tennessee Research Foundation Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs)
US9969683B2 (en) 2012-07-13 2018-05-15 Gtx, Inc. Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)
US9744149B2 (en) 2012-07-13 2017-08-29 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US9622992B2 (en) 2012-07-13 2017-04-18 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US10258596B2 (en) 2012-07-13 2019-04-16 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
LT2872482T (lt) 2012-07-13 2020-12-28 Oncternal Therapeutics, Inc. Krūties vėžių gydymo būdas selektyviu androgeno receptoriaus moduliatoriumi
US10314807B2 (en) 2012-07-13 2019-06-11 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
WO2014060639A1 (fr) 2012-10-19 2014-04-24 Fermion Oy Procédé pour la préparation d'ospémifène
US10441567B2 (en) 2014-01-17 2019-10-15 Ligand Pharmaceuticals Incorporated Methods and compositions for modulating hormone levels
PL3171866T3 (pl) * 2014-07-24 2021-04-06 Aspen Park Pharmaceuticals, Inc. Leczenie uderzeń gorąca i utraty masy kostnej indukowanych terapią deprywacji androgenów z zastosowaniem cis-klomifenu

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2464203A (en) 1943-05-21 1949-03-15 Boots Pure Drug Co Ltd Manufacture of dienoestrol
US2465505A (en) 1944-12-05 1949-03-29 Hoffmann La Roche Process for the manufacture of 3, 4-di-(p-hydroxy-phenyl)-hexadiene-2, 4
US2914562A (en) 1957-08-06 1959-11-24 Wm S Merrell Co Amine derivatives of triphenylethanol
GB2126576B (en) 1982-06-25 1985-06-19 Farmos Group Limited Alkane and alkene derivatives
US5491173A (en) 1982-06-25 1996-02-13 Orion-Yhtyma Oy Tri-phenyl alkene derivatives and their preparation and use
US4729999A (en) * 1984-10-12 1988-03-08 Bcm Technologies Antiestrogen therapy for symptoms of estrogen deficiency
ES2189784T3 (es) * 1989-07-07 2003-07-16 Endorech Inc Procedimiento para el tratamiento de enfermedades relacionadas con adrogenos.
GB9126209D0 (en) 1991-12-10 1992-02-12 Orion Yhtymae Oy Drug formulations for parenteral use
GB9207437D0 (en) 1992-04-03 1992-05-20 Orion Yhtymae Oy Topical administration of toremifene and its metabolites
US5468488A (en) * 1993-06-24 1995-11-21 Wahi; Ashok L. Electrostatically charged nasal application product and method
TW303299B (fr) * 1993-07-22 1997-04-21 Lilly Co Eli
DE19526146A1 (de) * 1995-07-07 1997-01-09 Schering Ag Triphenylethylene, Verfahren zu deren Herstellung, diese Triphenylethylene enthaltene pharmazeutische Präparate sowie deren Verwendung zur Herstellung von Arzneimitteln
IL120262A (en) * 1996-02-28 2001-01-28 Pfizer Droloxifene and derivatives thereof for use in increasing serum testosterone levels
US5859045A (en) * 1996-05-08 1999-01-12 Novo Nordisk A/S Novo Alle Crystalline -! 3R 4R-trans-7 methoxy 2,2-dimethyl1-3-phenyl 1-4 4-12 pyrrolidin-1 -Y1!ethoxyl 1!chromane hydrogen fumarate
US6413533B1 (en) 1998-05-07 2002-07-02 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
US6413534B1 (en) 1998-05-07 2002-07-02 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
DE69922131T2 (de) 1998-05-07 2005-11-24 The University Of Tennessee Research Corp., Knoxville Medikament zur behandlung intraepithelialer prostataneoplasie
US6632447B1 (en) 1998-05-07 2003-10-14 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
IL139587A0 (en) * 1998-06-16 2002-02-10 Pfizer Prod Inc Therapeutic combinations of (selective) estrogen receptor modulators (serm) and growth hormone secretagogues (ghs) for treating musculoskeletal frailty
EP1004306A3 (fr) * 1998-08-06 2000-06-07 Pfizer Products Inc. Agonistes/antagonistes de l'estrogène
EP1102582A2 (fr) * 1998-08-07 2001-05-30 Endorecherche Inc. INHIBITION DE LA 3$G(a)-HYDROXYSTEROID-DESHYDROGENASE DE TYPE 3
WO2000008001A1 (fr) * 1998-08-07 2000-02-17 Chiron Corporation Isoxazoles substitues comme modulateurs de recepteur d'oestrogenes
WO2000074684A1 (fr) * 1999-06-04 2000-12-14 The General Hospital Corporation Formulations pharmaceutiques pour traiter des femmes en periode de postmenopause et de perimenopause, et leur utilisation
DK1246814T3 (da) * 1999-12-30 2005-05-30 Signal Pharm Llc Forbindelser og fremgangsmåder til modulation af östrogenreceptorer
GB0012291D0 (en) * 2000-05-23 2000-07-12 Astrazeneca Ab Pharmaceutical combination
AU2001271163A1 (en) * 2000-07-05 2002-01-14 Astrazeneca Ab Pharmaceutical combination of an anti-androgen and tamoxifen for providing an anti-androgenic effect and aromatase inhibition

Also Published As

Publication number Publication date
TW200410711A (en) 2004-07-01
WO2003047504A2 (fr) 2003-06-12
EP1862165A2 (fr) 2007-12-05
ATE418972T1 (de) 2009-01-15
EP1460969A4 (fr) 2005-08-17
IL206646A0 (en) 2011-07-31
DE60226494D1 (de) 2008-06-19
HK1092066A1 (en) 2007-02-02
DK1666033T3 (da) 2009-04-06
US6899888B2 (en) 2005-05-31
ATE394099T1 (de) 2008-05-15
ES2305350T3 (es) 2008-11-01
EP1666033A1 (fr) 2006-06-07
HRP20040547A2 (en) 2005-08-31
EP1862165A3 (fr) 2008-06-25
MXPA04005112A (es) 2005-04-29
PT1460969E (pt) 2008-07-01
EA200400744A1 (ru) 2005-02-24
CA2468719A1 (fr) 2003-06-12
CN1679956A (zh) 2005-10-12
CN100548283C (zh) 2009-10-14
SI1666033T1 (sl) 2009-06-30
EP2098247A2 (fr) 2009-09-09
CA2468719C (fr) 2011-05-24
BR0214801A (pt) 2005-01-11
CY1108895T1 (el) 2014-07-02
EP2098247A3 (fr) 2010-05-26
KR100658110B1 (ko) 2006-12-14
JP2005247862A (ja) 2005-09-15
SI1460969T1 (sl) 2008-10-31
EP1460969A2 (fr) 2004-09-29
EP1574212A1 (fr) 2005-09-14
IL162144A0 (en) 2005-11-20
CA2537913A1 (fr) 2003-06-12
DE60230687D1 (de) 2009-02-12
EP1666033B1 (fr) 2008-12-31
HK1068104A1 (en) 2005-04-22
CY1108174T1 (el) 2014-02-12
AU2002356928A1 (en) 2003-06-17
EP1460969B1 (fr) 2008-05-07
WO2003047504A3 (fr) 2003-10-16
GEP20094841B (en) 2009-11-25
AU2008203121A1 (en) 2008-08-07
TWI315987B (en) 2009-10-21
AU2002356928B2 (en) 2008-04-17
ES2319785T3 (es) 2009-05-12
JP2005515988A (ja) 2005-06-02
PT1666033E (pt) 2009-02-09
CN1617691A (zh) 2005-05-18
KR20050044618A (ko) 2005-05-12
US20030153625A1 (en) 2003-08-14

Similar Documents

Publication Publication Date Title
DK1460969T3 (da) Forebyggelse og behandling af ved androgen-berövelse fremkaldt osteoporose
EP1446114A4 (fr) Compositions et methodes de traitement de l'osteoporose
IL140989A0 (en) Compositions and methods for treating osteoporosis and lowering cholesterol
IL159422A0 (en) Methods and compositions for treating or preventing skin disorders using binding agents specific for prostate-specific membrane antigen
DE60014873D1 (de) Synergistische zusammensetzungen zur krebsbehandlung
DK1446012T3 (da) Bakteriolytisk kombinationsterapi til behandling af tumorer
ATE414512T1 (de) Kombinationstherapie zur behandlung von krebs
EP1379242A4 (fr) Methode de traitement de cancers et compositions appropriees
IL158206A0 (en) Compositions and methods for the prevention and treatment of human prostate cancer
IL145397A0 (en) Compositions and methods for treatment of cancer
DK1272195T3 (da) Anvendelse af fulvestrant til behandling af resistent brystcancer
PL368035A1 (en) Compositions and methods for the treatment of cancer
DE60223707D1 (de) Calcium-l-threonat zur behandlung von knochenfrakturen
ZA200503026B (en) Benzopyranone compounds, compositions thereof, and methods for treating or preventing cancer
AU2002360454A8 (en) Methods and compositions for treating cancer
DK1379242T3 (da) Fremgangsmåde til behandling af cancer og sammensætninger til anvendelse derved
IL160816A0 (en) Compositions and methods for treatment of cancer
ZA200100675B (en) Compositions and methods for treating osteoporosis and lowering cholesterol.